New dosing strategy aims to tame blood cancer with fewer side effects
NCT ID NCT03961672
Summary
This study is testing whether giving the cancer drug duvelisib on an irregular schedule works as well as continuous dosing but with fewer severe side effects. It is for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to prior treatments. The main goal is to see if this approach keeps the cancer from progressing for at least 12 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.